Perineural incobotulinumtoxin-A for Complex Regional Pain Syndrome - An open-label feasibility study (PINCom)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519832-17-00

Enrollment

Registered

2025-10-13

Start date

2026-01-07

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome

Brief summary

Overall feasibility analysis of a full scale trial, based on patient and investigator feedback, recruitment-, inclusion- and, completion- percentages and rates

Detailed description

Documentation of flare-up symptoms post-injection, Qualiative analysis of patient interviews on treatment, effects, and participation burden., Estimates of effect size on pain reduction for use in future power calculations.

Interventions

DRUGXEOMIN 200 units powder for solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall feasibility analysis of a full scale trial, based on patient and investigator feedback, recruitment-, inclusion- and, completion- percentages and rates	—

Secondary

Measure	Time frame
Documentation of flare-up symptoms post-injection, Qualiative analysis of patient interviews on treatment, effects, and participation burden., Estimates of effect size on pain reduction for use in future power calculations.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026